Erratum to "Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?" [J Hepatol 46 (2007) 6-8] (DOI:10.1016/j.jhep.2006.10.008);Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?

Journal of Hepatology

Volumn 46, Issue 1, 2007, Pages 6-8

  Lau, George K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBUVIDINE;

ANTIVIRAL ACTIVITY; DISEASE COURSE; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 33751514296     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.03.001     Document Type: Erratum

References (16)

1. He J., Gu D., Wu X., Reynolds K., Duan X., Yao C., et al. Major causes of death among men and women in China. N Engl J Med 353 (2005) 1124-1134
2. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Koida I., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 28 (1998) 930-938
3. Liaw Y.F., Tai D.I., Chu C.M., and Chen T. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
4. Fattovich G., Brollo L., Giustina G., Noventa F., Pontisso P., Alberti A., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 32 (1991) 294-298
5. Realdi G., Fattovich G., Hadziyannis S., Schalm S.W., Almasio P., Sanchez-Tapias J., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 21 (1994) 656-666
6. de Franchis R., Meucci G., Vecchi M., Tatarella M., Colombo M., Del Ninno E., et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Int Med. 118 (1993) 191-194
7. Fattovich G., Giustina G., Schalm S.W., Hadziyannis S., Sanchez-Tapias J., Almasio P., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis. Hepatology 21 (1995) 77-82
8. Hui C.K., and Lau G.K. Current issues and future directions in treatment. Semin Liver Dis 26 (2006) 192-197
9. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Risk evaluation of viral load elevation and associated liver disease/cancer - In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
10. Yu M.W., Yeh S.H., Chen P.J., Liaw Y.F., Lin C.L., Liu C.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97 (2005) 265-272
11. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
12. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., and Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
13. Fattovich G., Giustina G., Realdi G., Corrocher R., and Schalm S.W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European concerted action on viral hepatitis (EUROHEP). Hepatology 26 (1997) 1338-1342
14. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
15. Lin S.-M., Yu M.-L., Lee C.-M., Chien R.-N., Sheen I.-S., Chu C.-M., and Liaw Y.-F. Interferon therapy in HBeAg positive chronic hepatitis reduce cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
16. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a HBeAg-positive chronic hepatitis B study group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695